Dr. Bray Links

Wednesday, November 14, 2018

AHA.18: Nonstatin therapies, CAC testing claim larger role in cholesterol guidelines

New cholesterol guidelines from the American Heart Association (AHA) and the American College of Cardiology (ACC) recommend adding ezetimibe and/or PCSK9 inhibitors to statin therapy for select high-risk patients, and also propose using coronary artery calcium scoring as "a tiebreaker" to guide statin decisions for those at intermediate risk of atherosclerotic cardiovascular disease (ASCVD).

"How we treat and how we prevent (CVD) can vary from patient to patient," said ACC vice president Richard Kovacs, MD. "This guideline gives clinicians the tools that we need to have those conversations with patients about the most appropriate treatment for high cholesterol."

The 121-page guideline, which was presented Nov. 10 at the AHA's Scientific Sessions in Chicago, was also published online in Circulation and the Journal of the American College of Cardiology.

https://www.cardiovascularbusiness.com/topics/lipids-metabolic/nonstatin-therapies-cac-screening-headline-new-cholesterol-guidelines

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.